Azad Saei

Azad Saei


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWen Jing Sim
Wen Jing Sim
PIPrasanna Vasudevan Iyengar
Prasanna Vasudevan Iyengar
DLDilraj Lama
Dilraj Lama
SLSarah Kit Leng Lui
Sarah Kit Leng Lui
HNHsien Chun Ng
Hsien Chun Ng
JTJEAN PAUL THIERY
JEAN PAUL THIERY
Treatment of muscle-invasive bladder cancer remains a major clinical challenge. Aberrant HGF/c-MET upregulation and activation is frequently observed in bladder cancer correlating with cancer progression and invasion. However, the mechanisms underlying HGF/c-MET-mediated invasion in bladder cancer remains unknown. As part of a negative feedback loop SMAD7 binds to SMURF2 targeting the TGFβ receptor for degradation. Under these conditions, SMAD7 acts as a SMURF2 agonist by disrupting the intramolecular interactions within SMURF2. We demonstrate that HGF stimulates TGFβ signalling through c-SRC-mediated phosphorylation of SMURF2 resulting in loss of SMAD7 binding and enhanced SMURF2 C2-HECT interaction, inhibiting SMURF2 and enhancing TGFβ receptor stabilisation. This upregulation of the TGFβ pathway by HGF leads to TGFβ-mediated EMT and invasion. In vivo we show that TGFβ receptor inhibition prevents bladder cancer invasion. Furthermore, we make a rationale for the use of combinatorial TGFβ and MEK inhibitors for treatment of high-grade non-muscle-invasive bladder cancers.

7 June 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ASAzad Saei
Azad Saei
MPMarta Palafox
Marta Palafox
Touati BenoukrafTouati Benoukraf
Touati Benoukraf
NKNishi Kumari
Nishi Kumari
PJPatrick William Jaynes
Patrick William Jaynes
PEPieter Eichhorn
Pieter Eichhorn
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of upstream signaling. Here, we demonstrate that the deubiquitinating enzyme USP28 functions through a feedback loop to destabilize RAF family members. Loss of USP28 stabilizes BRAF enhancing downstream MAPK activation and promotes resistance to RAF inhibitor therapy in culture and in vivo models. Importantly, we demonstrate that USP28 is deleted in a proportion of melanoma patients and may act as a biomarker for response to BRAF inhibitor therapy in patients. Furthermore, we identify Rigosertib as a possible therapeutic strategy for USP28-depleted tumors. Our results show that loss of USP28 enhances MAPK activity through the stabilization of RAF family members and is a key factor in BRAF inhibitor resistance.

1 December 2017 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
NKNishi Kumari
Nishi Kumari
PJPatrick William Jaynes
Patrick William Jaynes
ASAzad Saei
Azad Saei
PIPrasanna Vasudevan Iyengar
Prasanna Vasudevan Iyengar
John Lalith Charles RichardJohn Lalith Charles Richard
John Lalith Charles Richard
PEPieter Eichhorn
Pieter Eichhorn

14 May 2013 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ASAzad Saei
Azad Saei
JHJamshid Hadjati
Jamshid Hadjati
Dendritic cells (DCs) as professional antigen-presenting cells are able to induce immunity and tolerance in different conditions, which leads to strong immune responses against hostile agents or tolerance to self-antigens. Although for subsets of DCs, a regulatory function has been shown, the role of the microenvironment is momentous to generate tolerogenic DCs (tDCs). Different microorganisms and tumor cells escape from immune responses by producing mediators and components that influence DCs to show tolerogenic characteristics. In this review, tDC induction was explained in steady state and disease conditions. Moreover, an overview was presented on the efforts to generate in vitro tDCs, their clinical applications and the problems which remain to be solved in this field.

14 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ASAzad Saei
Azad Saei
PEPieter Eichhorn
Pieter Eichhorn
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific oncogenic mutations induce a number of intrinsic compensatory mechanisms, also known as adaptive responses or feedback loops, that enhance the pro-survival and pro-proliferative capacity of a proportion of the original tumour population, thereby resulting in tumour progression. In this review we will summarize the known adaptive responses that limit BRAF mutant therapy and discuss potential novel combinatorial therapies to overcome resistance.

1 December 2013
Verified
Journal Article
Closed access
SFSasan Fallahi
Sasan Fallahi
MMMahdi Mahmoudi
Mahdi Mahmoudi
SSSajjad Shekarchian
Sajjad Shekarchian
FGFarhad Gharibdoost
Farhad Gharibdoost
EFElham Farhadi
Elham Farhadi
AJAhmad Reza Jamshidi
Ahmad Reza Jamshidi